Mammographic breast density and breast cancer risk in a Mediterranean population: a nested case –control study in the EPIC Florence cohort
ConclusionsWe confirm in this Mediterranean population the association of increasing MBD, classified according to BI-RADS with BC risk also taking into account other well-known risk factors for this neoplasm.
Conclusions We concluded that different races/ethnicities had different breast cancer related reproductive risk factors. Non-Hispanic Caucasians had the most breast cancer related reproductive risk factors, while the minorities had none or few breast cancer related reproductive risk factors and among these few factors only 1 was also risk factor for non-Hispanic Caucasians.
Clinical Endocrinology, EarlyView.
Title: Hormone Therapy in Survivors of Breast CancerCategory: Doctor's&Expert's views on SymptomsCreated: 5/31/2001 12:00:00 AMLast Editorial Review: 6/13/2018 2:55:07 PM
Conclusions: The presence of the G/G genotype of XbaI may be considered a susceptibility allele in Mexican women. Due to increased postmenopausal BC risk, the XbaI (WT/G or G/G) alleles may be used as a postmenopausal predictive factor for BC in Mexican women.
Conclusion: Based on our results, we concluded that modified Bloom–Richardson (MBR) grading has been recognized as a treatment related indicator. The accuracy and reliability in grading have always been a matter of concern, hence, the reproducibility of grading should be enhanced. Ki-67-a proliferation marker is easily identified and provides comparable accurate information. In contrast to poor reproducibility of mitotic counts, Ki-67 can achieve high agreement between pathologists; is more reproducible; adds complementary value to the MBR grading system and correlates well with other clinicopathologic parameters. It...
Conclusion: Palbociclib has clinical activity as a single agent in women with moderately pre-treated, oestrogen receptor-positive, HER2-negative advanced breast cancer. Palbociclib may have potential to reverse endocrine resistance in patients with a history of previous durable response to ET. Clinical trial information: NCT02549430. PMID: 29893790 [PubMed - as supplied by publisher]
ConclusionBreast density is an independent and significant risk factor for development of contralateral breast cancer. This risk factor should contribute to clinical decision making.
ConclusionsOur results do not support associations between T2DM and/or GDM and higher amount of mammographically dense breast tissue, suggesting that the mechanism linking diabetes with breast cancer risk may not include mammographic breast density in midlife.
Phyllis Lacetti found her own breast cancer when she felt an abnormal lump in her right breast in 2007. A nurse at Montefiore Medical Center, she had a lumpectomy to remove it, but an MRI afterward revealed remaining cancer cells, so she opted to get a mastectomy. Her cancer doctor recommended she get chemotherapy to ensure that her cancer wouldn’t recur, since Lacetti’s family history put her at high risk. Her sister and father had died of leukemia, and her brother passed away from thyroid cancer. Chemotherapy, he said, was her best option for preventing the cancer from returning. But Lacetti was reticent abo...
This study aims to assess the patterns of development of on-treatment cardiac side effects among patients with early breast cancer receiving anthracycline-based chemotherapy. METHODS: This is a pooled analysis of patient-level data of patients with early-stage breast cancer who were recruited into three clinical trials to receive different adjuvant chemotherapy regimens. Univariable and multivariable analyses of factors predicting the development of on-treatment cardiac adverse events were conducted through logistic regression analysis. The following factors were evaluated in the univariable analysis: age, menopausal ...